FDA approval of a generic carfilzomib ANDA expanding access to this proteasome inhibitor formulation.
Reported
Approval date2026-07-20
Application numberANDA209526
Submission typeORIG
Loading
Drug or technology
1 development in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
FDA approval of a generic carfilzomib ANDA expanding access to this proteasome inhibitor formulation.